NEUROD1 and glioblastoma: We developed a self-complementary adeno-associated virus (scAAV) vector, scAAV6-NeuroD1, and evaluated its therapeutic potential across <i>in vitro</i> and <i>in vivo</i> GBM models, including multiple GBM cell lines, patient-derived organoids, and orthotopic models in immunodeficient mice.